Key result
Transient elastography liver stiffness fails to predict adverse events but reliably excludes advanced liver disease.
Why the study?
Does liver stiffness measured by transient elastography predict adverse events in adult patients with Fontan associated liver disease?
Cohort (n=167)
Does liver stiffness measured by transient elastography predict adverse events in adult patients with Fontan associated liver disease?
Liver stiffness measured by transient elastography does not predict adverse events in young adult patients with Fontan circulation, though it can help discriminate advanced Fontan-associated liver disease.
Suggests transient elastography should not be used in isolation for prognostication in Fontan.
Background Fontan associated liver disease (FALD) is a known complication in adult patients with total cavo-pulmonary connection. The relationship between the severity of FALD and cardiovascular disease progression is yet to be clarified. We investigated the role of liver stiffness measured by transient elastography (TE) in predicting adverse events (AEs) in adult patients with Fontan circulation. Material and methods We retrospectively analysed TE data from our cohort of Fontan patients from September 2014 to December 2023. Baseline characteristics were recorded. The association of TE, liver function tests, and pro-collagen3 with AEs were analysed. Results 167/207 patients (median age 20.0 years; 60% male) for a total of 613 TE from September 2014 to December 2023 (median follow up 56.0 months; 1.893 patient-year) were included in the study. TE values remained stable over time and did not show any correlation with baseline characteristics. TE values <23.9kPa could discriminate patients with advanced FALD (Se 50%; Sp 79%; NPV 97%). Forty AEs occurred (0.06 events per patient-year). High albumin was the only significant factor associated with AEs at multivariate analysis (HR 0.18, p 0.009). Conclusions In this relatively young cohort, with low mortality and no HCC during follow-up, no significant association was found between TE and AEs. Nevertheless, TE appeared to be useful in discriminating advanced FALD. As no convincing risk factor related to FALD severity or progression has been yet identified, a multidisciplinary approach to risk assessment and surveillance is advised to reduce the impact of FALD and prevent progression to HCC.
No takes yet. Share an insight, caveat, or question.
Pomiato et al. (2026) conducted a cohort in Fontan associated liver disease (FALD) (n=167). Transient elastography (TE) was evaluated on Adverse events (AEs). Liver stiffness measured by transient elastography did not predict adverse events (0.06 events per patient-year), but values <23.9 kPa discriminated advanced liver disease (NPV 97%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: